Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopesnews2024-01-03T14:25:24+00:00January 3rd, 2024|Endpoints News|
Novo Nordisk eyes further European manufacturing expansion as it buys land in Irelandnews2024-01-03T14:15:14+00:00January 3rd, 2024|Endpoints News|
Invivyd requests emergency use authorization for Covid-19 preventive antibody among immunocompromisednews2024-01-03T12:13:35+00:00January 3rd, 2024|Endpoints News|
Goldman Sachs closes $650M life sciences fund to bankroll industry’s ‘golden era’news2024-01-03T12:04:57+00:00January 3rd, 2024|Endpoints News|
Roche lines up RNA pact with Remix Therapeutics, which also raised another $60Mnews2024-01-03T12:00:04+00:00January 3rd, 2024|Endpoints News|
NGM Bio subject of take-private bid by institutional investor The Column Groupnews2024-01-03T11:30:53+00:00January 3rd, 2024|Endpoints News|
Bladder cancer drugmaker CG Oncology files for IPO as biotech market shows signs of a reboundnews2024-01-03T07:55:58+00:00January 3rd, 2024|Endpoints News|
Yale Law School’s free speech group says Boehringer’s IRA argument is ‘fundamentally flawed’news2024-01-02T19:48:51+00:00January 2nd, 2024|Endpoints News|
Court grants FTC injunction over IQVIA’s deal with Propel Media and DeepIntentnews2024-01-02T19:17:32+00:00January 2nd, 2024|Endpoints News|
Beyfortus approved in China to protect infants from RSV; Illumina investor files class action suitnews2024-01-02T19:14:13+00:00January 2nd, 2024|Endpoints News|
